SIMPLIFication of Care Pathways for Patients with Rare Brain Tumors Through Artificial Intelligence
Launched by FONDAZIONE I.R.C.C.S. ISTITUTO NEUROLOGICO CARLO BESTA · Mar 12, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on improving care for patients with rare brain tumors, which are unusual and can differ greatly from one another. The main goal is to create better treatment plans using Artificial Intelligence (AI) to help predict how well patients might recover after surgery. The study will involve gathering information about patients' health and mental well-being over time. Participants will also take part in a special rehabilitation program at home to help them regain cognitive skills using a program called RehaCom.
To be eligible for this study, participants must be adults (18 years or older) who have been diagnosed with rare brain tumors and are scheduled for surgery. They should also be able to speak Italian for assessments and rehabilitation. Those with certain psychiatric issues, severe cognitive decline, or who do not have the necessary technology for the program will not be included. By taking part in this trial, patients will have the chance to receive personalized care that aims to improve their quality of life after treatment.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults (age ≥18 years)
- • Both sexes
- • Patients with rare brain tumors (incidence \<6 cases per 100,000 people/year)
- • Candidates for craniotomy for rare brain tumors
- • Native Italian speakers for cognitive and psychological evaluation and neuro-cognitive rehabilitation
- Exclusion Criteria:
- • Patients undergoing stereotactic/frameless biopsy
- • Patients with psychiatric disorders or on psychotropic medications
- • Patients with known cognitive decline (not due to the lesion)
- • Patients admitted on the same day as the surgery
- • Patients with severe impairments referred to rehabilitation centers
- • Patients without a Windows PC or laptop with Internet connection for neuro-cognitive rehabilitation
About Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta is a prestigious research institute in Italy dedicated to advancing the field of neurology through innovative clinical trials and translational research. As a leading center of excellence, it focuses on the diagnosis and treatment of neurological disorders, fostering collaboration among clinicians, researchers, and healthcare professionals. The foundation is committed to improving patient outcomes by integrating cutting-edge scientific research with clinical practice, ensuring that groundbreaking therapies and interventions are effectively translated into real-world applications for individuals affected by neurological conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Milano, Pa, Italy
L'aquila, , Italy
Patients applied
Trial Officials
Paolo Ferroli, MD
Principal Investigator
Fondazione IRCCS Istituto Neurologico Carlo Besta
Alessandro Ricci, MD
Principal Investigator
ASL 1 Abruzzo Avezzano-Sulmona-L'Aquila
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported